The Day In Review: BioSimilar Drug Enters Trial

March 21, 2007 -- BioGeneriX AG and Neose Technology began the second Phase I trial of a competitor to Amgen’s Neulasta, as the war over biosimilar drugs heats up; Artes Medical requested FDA permission to claim five-year efficacy for its injectable anti-wrinkle treatment, ArteFill; Encysive began treating patients in a Phase II trial of a hypertension drug candidate; Emergent BioSolutions submitted an IND for its Anthrax Immune Globulin drug candidate; Aegerion Pharma filed to raise $86 million in an IPO; UCB received FDA permission to add another type of seizure on the label of Keppra; and Illumina launched its BeadXpress System. The Centient Biotech 200™ climbed 58 points to 3920, a gain of 1.50%. More details...